1. Market Research
  2. > Biotechnology
  3. > Medical Biotechnology Market Trends
Cancer Immunotherapy Market Analysis Report By Product, By Cancer Type And Segment Forecasts, 2019 - 2026

Cancer Immunotherapy Market Analysis Report By Product, By Cancer Type And Segment Forecasts, 2019 - 2026

  • February 2019
  • 120 pages
  • ID: 5214652
  • Format: PDF

Summary

Table of Contents

Cancer Immunotherapy Market Analysis Report By Product (Oncolytic Viral Therapies & Cancer Vaccines, Monoclonal Antibodies, Immunomodulators), By Cancer Type (Breast, Lung), and Segment Forecasts, 2019 - 2026

The global cancer immunotherapy market size is likely to reach USD 126.9 billion by 2026, exhibiting a CAGR of 9.6% during the forecast period. Increasing patient pool and higher mortality rate are augmenting the need for cancer immunotherapy globally. Furthermore, increasing number of approvals for new immunotherapeutic drugs is driving the global market.

Cancer immunotherapy has emerged as a new avenue for revenue generation for pharmaceutical companies.In addition, adverse effects, such as recurrence of cancer and organ failure, associated with conventional chemotherapies and rising demand for technologically advanced healthcare solutions are boosting the demand for immunotherapies.

Moreover, introduction of newer drug classes, such as target receptors for multiple myeloma and checkpoint inhibitors, is poised to make way for advanced therapeutics in the market.

Introduction of new molecules has been proving to be beneficial for patients who are not responding to chemotherapy. Several new immunotherapeutic options, such as immunomodulators and CAR-T cell therapy, are in the pipeline and are being tested for their ability to provide better cancer treatment.

Monoclonal antibodies are the most widely used immunotherapeutic drugs globally.Development of monoclonal antibodies as effective immunotherapeutic options started after the approval of Blincyto (blinatumomab) by Amgen, a bispecific antibody that targets B-cell lymphoblastic leukemia.

Increasing R&D pertaining to the use of monoclonal bodies as naked antigen binding antibodies, conjugated, and bispecific antibodies is resulting in discovery of new therapeutic options for cancer treatment.

Further key findings from the report suggest:
• Majority of immunotherapy drugs are being used in treatment of cancer of lung, breast, and prostate
• Monoclonal antibodies emerged as the largest segment because of increasing regulatory approvals and higher efficacy
• Lung cancer accounted for the largest share in 2018 and will continue to dominate the market through 2025
• North America was the leading revenue contributor in the market in 2018. Rising incidence of cancer and increasing demand for novel technologies are facilitating the dominance of the region during the forecast period
• Europe is projected to witness rapid growth during the forecast period owing to rapid adoption of advanced cancer therapeutics for effective treatment
• Some of the key players are Amgen, Inc.; AstraZeneca; F. Hoffmann La Roche Ltd.; Bayer AG; Bristol-Myers Squibb Company; Eli Lilly and Company; Merck and Co., Inc.; Novartis AG; and Pfizer, Inc.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Pipeline Review, H1 2019

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Pipeline Review, H1 2019

  • $ 3500
  • March 2019

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Pipeline Review, H1 2019SummaryAccording to the recently published report ’Toll Like Receptor 4 - Pipeline Review, H1 2019’; Toll Like Receptor 4 (hToll ...

Anal Cancer - Pipeline Review, H1 2019

Anal Cancer - Pipeline Review, H1 2019

  • $ 2000
  • March 2019

Anal Cancer - Pipeline Review, H1 2019SummaryGlobal Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Anal Cancer - Pipeline Review, H1 2019, provides an overview of the Anal ...

Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Pipeline Review, H1 2019

Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Pipeline Review, H1 2019

  • $ 3500
  • March 2019

Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Pipeline Review, H1 2019SummaryTumor Necrosis Factor Receptor Superfamily ...


ref:plp2019

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on